Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Vertical transmission and humoral immune response following maternal infection with SARS-CoV-2 - A prospective multicenter cohort study
  • +6
  • Manal Massalha,
  • Enav Yefet,
  • Orit Rozenberg ,
  • Sofia Soltsman ,
  • Jamal Hasanein ,
  • Tatiana Smolkin ,
  • Adi Alter ,
  • Yuri Perlitz,
  • Zohar Nachum
Manal Massalha
Emek Medical Center

Corresponding Author:[email protected]

Author Profile
Enav Yefet
Emek Medical Center
Author Profile
Orit Rozenberg
Emek Medical Center
Author Profile
Sofia Soltsman
Baruch Padeh Medical Center Poriya
Author Profile
Jamal Hasanein
Emek Medical Center
Author Profile
Tatiana Smolkin
Baruch Padeh Medical Center Poriya
Author Profile
Adi Alter
Baruch Padeh Medical Center Poriya
Author Profile
Yuri Perlitz
The Baruch Padeh Medical Center, Poriya. Affiliated to the Faculty of Medicine in the Galilee. Bar-Ilan University Safed, Israel.
Author Profile
Zohar Nachum
Emek Medical Center
Author Profile

Abstract

Objective: To explore maternal humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the rate of vertical transmission. Design: A prospective cohort study. Setting: Two university-affiliated medical centers in Israel. Population: Women positive for SARS-CoV-2 reverse-transcription-polymerase-chain-reaction (RT-PCR) test, during pregnancy were enrolled just prior to delivery. Methods: Levels of anti-SARS-CoV-2 spike-IgM, spike-IgG and nucleocapsid-IgG were tested in maternal and cord blood at delivery, and neonatal nasopharyngeal swabs were subjected to PCR testing. Main outcomes measures: The primary endpoint was the rate of vertical transmission, defined as either positive neonatal IgM, positive neonatal IgG with sero-negative mother or positive neonatal PCR. Results: Among 72 women, 36 (50%), 39 (54%) and 30 (42%) were positive for anti-spike-IgM, anti-spike-IgG and anti-nucleocapsid-IgG, respectively (p<0.0001 for IgG antibodies-comparison). At least 8/72 (11%) neonates were infected in utero; one had a positive PCR result and seven had positive IgG antibodies while their mothers were seronegative for the same IgG. IgM was not detected in cord blood. Anti-nucleocapsid-IgG and anti-spike-IgG were detected in 83% and 85% of neonates of seropositive mothers, respectively (Pearson coefficient correlation 0.8, p<0.001). The highest rate of positive maternal serology tests was 8-12 weeks post-infection (89% anti-spike IgG, 78% anti-spike-IgM and 67% anti-nucleocapsid-IgG). Thereafter, the rate of positive serology tests declined gradually; at 20 weeks post-infection, only anti-spike-IgG was detected in 33-50%. Conclusions: The rate of vertical transmission was at least 11%. Vaccination should be considered 3 months post-infection in pregnant women due to a decline in antibody levels.